 |
|
|
| |
PROJECTED IMPACT OF ELBASVIR/GRAZOPREVIR IN TREATMENT-NÁVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 AND CHRONIC KIDNEY DISEASE IN VIETNAM
|
| |
| |
Reported by Jules Levin
APASL 2017 Feb 15-19 Shanghai, China
Chizoba Nwankwo, PhD;1 Elamin H. Elbasha, PhD;1 Thuy Thi Thu Nguyen, PhD, MBA;2 Nguyen Khac Luong Quang, MD, PhD;3 Shelby Corman, PharmD, MS, BCPS;4 1. Merck & Co., Inc., Kenilworth, NJ, USA 2. University of Medicine and Pharmacy, Ho Chi Minh city, Vietnam 3. Merck Sharp & Dohme, Ho Chi Minh city, Vietnam 4. Pharmerit International, Bethesda, M
"reduce lifetime cumulative incidence of decompensated cirrhosis -
....incidence of hepatocellular carcinoma
....reduced End-stage Liver Disease mortality
....extended life expectancy
.......projected higher average discounted quality-adjusted life years"
D, USA
1. Van K.N. et al Renal Society of Australasia Journal 2012;8(3):140-145; 2. DDD; 3. Roth D. et al Lancet 2015 Oct 17;386(10003):1537-45
|
| |
|
|
|
|
|
